Helix BioPharma Corp. Closes Private Placement, Extends Period to Exercise Warrants and Provides Corporate Update

NEXT STORY
Praluent® (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease
PREV STORY
Akcea and Ionis Announce Upcoming Data Presentations at the 2019 American College of Cardiology Meeting (ACC.19)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

NewLink Genetics Prices Public Offering of Common Stock

AMES, Iowa, Oct. 03, 2017 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (“NewLink Genetics”) (Nasdaq:NLNK), a ...

author_avatar
NASDAQ Market News

Covis Enters Promotion and Distribution Agreement for Two Respiratory Medicines, Seebri® Breezhaler® and Ultibro® Breezhaler®, in Canada

author_avatar
NASDAQ Market News

OSE Immunotherapeutics to Present New Data on OSE-172 at American Association for Cancer Research Annual Meeting 2018, in Chicago, April 14-18

OSE-172, SIRPa Antagonist: Prevents Metastasis Spread in Aggressive Cancer Models;Decreases Tumor Growth and Suppressive ...

author_avatar
NASDAQ Market News